Coverage of GLP-1 weight loss drugs is being phased out by a growing number of large U.S. employers heading into 2027, a trend driven by climbing overall costs that have persisted even as the per-unit price of individual medications has declined. The trend is documented in a survey from Business Group on Health, a nonprofit health policy organization focused on large employers, which found that ro…
